Register entry

Incyte Corporation

Registered sites
0
Drug products
22
Live patents
273
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Exclusivity

Patents

273

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
JAKAFIRUXOLITINIB PHOSPHATEDec 2026
JAKAFIRUXOLITINIB PHOSPHATEJun 2027
JAKAFIRUXOLITINIB PHOSPHATEDec 2027
JAKAFIRUXOLITINIB PHOSPHATEJun 2028
JAKAFIRUXOLITINIB PHOSPHATEJun 2028
JAKAFIRUXOLITINIB PHOSPHATEDec 2028
JAKAFI XRRUXOLITINIB PHOSPHATEDec 2026
JAKAFI XRRUXOLITINIB PHOSPHATEDec 2027
JAKAFI XRRUXOLITINIB PHOSPHATEJun 2028
JAKAFI XRRUXOLITINIB PHOSPHATEJun 2028
JAKAFI XRRUXOLITINIB PHOSPHATEDec 2028
JAKAFI XRRUXOLITINIB PHOSPHATENov 2033
JAKAFI XRRUXOLITINIB PHOSPHATEJan 2034
JAKAFI XRRUXOLITINIB PHOSPHATEMay 2034
JAKAFI XRRUXOLITINIB PHOSPHATEJul 2034
OPZELURARUXOLITINIB PHOSPHATEDec 2026
OPZELURARUXOLITINIB PHOSPHATEJun 2027
OPZELURARUXOLITINIB PHOSPHATEDec 2027
OPZELURARUXOLITINIB PHOSPHATEJun 2028
OPZELURARUXOLITINIB PHOSPHATEJun 2028
OPZELURARUXOLITINIB PHOSPHATEDec 2028
OPZELURARUXOLITINIB PHOSPHATEMay 2031
OPZELURARUXOLITINIB PHOSPHATENov 2031
OPZELURARUXOLITINIB PHOSPHATEJun 2040
OPZELURARUXOLITINIB PHOSPHATEJul 2040
OPZELURARUXOLITINIB PHOSPHATESept 2040
OPZELURARUXOLITINIB PHOSPHATEMay 2041
PEMAZYREPEMIGATINIBApr 2034
PEMAZYREPEMIGATINIBJan 2035
PEMAZYREPEMIGATINIBMay 2039
PEMAZYREPEMIGATINIBAug 2040
PEMAZYREPEMIGATINIBOct 2040
Catalogue

Marketed products

22

Showing 22 of 22.

BrandGeneric nameFormCategory
JAKAFIruxolitinibTABLETNDA
JAKAFIruxolitinibTABLETNDA
JAKAFIruxolitinibTABLETNDA
JAKAFIruxolitinibTABLETNDA
JAKAFIruxolitinibTABLETNDA
JAKAFI XRruxolitinibTABLET, EXTENDED RELEASENDA
JAKAFI XRruxolitinibTABLET, EXTENDED RELEASENDA
JAKAFI XRruxolitinibTABLET, EXTENDED RELEASENDA
JAKAFI XRruxolitinibTABLET, EXTENDED RELEASENDA
JAKAFI XRruxolitinibTABLET, EXTENDED RELEASENDA
MONJUVITafasitamab-cxixINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONBLA
MONJUVITafasitamab-cxixINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONBLA
NIKTIMVOaxatilimab-csfrINJECTIONBLA
NIKTIMVOaxatilimab-csfrINJECTIONBLA
NIKTIMVOaxatilimab-csfrINJECTIONBLA
NIKTIMVOaxatilimab-csfrINJECTIONBLA
NIKTIMVOaxatilimab-csfrINJECTIONBLA
OPZELURAruxolitinibCREAMNDA
PEMAZYREpemigatinibTABLETNDA
PEMAZYREpemigatinibTABLETNDA
PEMAZYREpemigatinibTABLETNDA
ZYNYZretifanlimab-dlwrINJECTIONBLA
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.